MIRACL: Primary Efficacy Measure Relative risk = 0.84 P=0.048 95% CI 0.701-0.999 Atorvastatin Placebo 0 5 10 15 0481216 Time since randomization (weeks) Cumulative Incidence (%) Time to first occurrence of: Death (any cause) Non-fatal MI Resuscitated cardiac arrest Worsening angina with new objective evidence and urgent rehospitalization 17.4% 14.8%
{}